Diadem’s goal is to be the first truly blood-based Prognostic (Px) test for early detection of dementia in Neurodegenerative disease with a particular focus to Alzheimer’s Disease. Diadem has developed a unique/novel solution to one of the biggest problems in Neurodegenerative disease and in particular in early, accurate, predictive, fast, non-invasive and cost effective diagnosis in Alzheimer’s disease, which should enable improve treatment and the overall improvement in patient treatment/outcomes. Diadem was founded in 2012 as a spin-off of University of Brescia (Italy) and preparing for rapid commercialisation of its product via a global launch with strategic partners in 2021, additionally the Company is planning to carrying out further retrospective and prospective clinical trials to further validate its clinical claims.
Location: Italy, Lombardy
Employees: 1-10
Total raised: $12.75M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Panakes Pa... | panakes.it |
| 20.04.2022 | CDP Ventur... | en.cdpvent... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.03.2022 | - | $11.05M | - |
| 21.12.2018 | Series A | $1.71M | Panakes Pa... |
Mentions in press and media 5
| Date | Title | Description |
| 10.07.2024 | Diadem Appoints Michael Rasche as Chief Executive Officer | MILAN, July 10, 2024 (GLOBE NEWSWIRE) -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer’s disease (AD), today announced that Michael R... |
| 29.03.2022 | Italian startup Diadem raises €10M to develop a platform for early Alzheimer’s detection | Brescia, Italy-based Diadem SpA, a company developing the first blood-based test for the early prediction of Alzheimer‘s disease (AD), announced on Monday that it has raised €10M in the first tranche of its equity funding. This new funding ... |
| 29.03.2022 | Diadem Holds First Closing of €10M Equity Financing | Diadem SpA, a Milan, Italy-based developer of a blood-based test for the early prediction of Alzheimer’s disease (AD), closed the first tranche of a €10m equity financing. The round was led by new investor CDP Venture Capital and existing i... |
| 26.08.2021 | Diadem Announces Publication of Clinical Data Showing Its AlzoSure® Biomarker Test Accurately Predicts Progression to Alzheimer's Disease Six Years Before Diagnosis | MILAN, Aug. 26, 2021 /PRNewswire/ -- Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced results from a retrospective longitudinal study of its Alz... |
| 21.12.2018 | Diadem, an academic spin-off active in early Alzheimer diagnostic, raises €1,5 million in its A Round led by Panakes Partners | Diadem, an academic spin-off active in early Alzheimer diagnostic, raises €1,5 million in its A Round led by Panakes Partners Panakès Partners has led an investment round of ca. €1,5 million in Diadem an innovative startup based in Milan an... |